

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Lauermann
Serial No. 10/651,584 : Group Art Unit: 1614
Filed: August 30, 2003 : Examiner: Joseph S. Kudla
For: TARGETED RELEASE



AMENDMENT AND RESPONSE

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir/Madam:

In response to the Office Action dated 03/12/08, Applicant submits the following remarks within the statutory one (1) month period. No extension time is requested. No new matter has been added.

REMARKS

Election of Species

Applicant is making an election of species for examination purposes of the invention with traverse.

First Moiety

An antibody, more specifically an immunoglobulin G (IgG) is elected. The species in the claim have common denominator, a moiety that binds, inhibits, suppresses, neutralizes, or decreases activity of a biologically active agent.

Type of Inhibitor

An interleukin inhibitor, more specifically an anti-IL-2 antibody is elected. The species in the claim have common denominator, a biological inhibitor.

Active Agent

An interleukin, more specifically an interleukin-2 (IL-2) is elected. The species in the claim have common denominator, an agent having a biological activity.

Second Moiety

A peptide comprising a sequence specifically cleavable by a prostate specific antigen (PSA) protease is elected, such peptide could have a sequence HSSKLQ. The species in the claim have common denominator, a sequence cleavable by a reagent, more specifically a protease, even more specifically a prostate specific antigen (PSA) protease.

Reagent

A prostate specific antigen (PSA) protease is elected. The species in the claim have common denominator, an enzyme more specifically a protease.

Conclusion

It is believed that all of the stated requirements have been met. Applicant respectfully requests that the Examiner gives due consideration to the allowability of pending Claims, which are believed to recite subject matter that is patentable. An early action allowing the pending Claims is cordially solicited.

AUTHORIZATION

If further extension of time is necessary to prevent abandonment of this application, then such extension of time are hereby petitioned under 37 CFR 1.136(a).

Respectfully submitted,

Vit Lauermann
Vit Lauermann, PhD, Inventor

7904 Springway Rd.
Baltimore, MD 21204
Phone 410 828 0944
FAX 410 821 7850